Immix Biopharma Short Ratio vs. Current Ratio
| IMMX Stock | USD 2.11 0.14 7.11% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.8 | 0.9 |
|
| |||||
| Net Profit Margin | 0.0735 | 0.0827 |
|
| |||||
| Operating Profit Margin | 0.0734 | 0.0826 |
|
| |||||
| Pretax Profit Margin | 0.0734 | 0.0826 |
|
|
For Immix Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immix Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immix Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immix Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immix Biopharma over time as well as its relative position and ranking within its peers.
Immix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. If investors know Immix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immix Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Return On Assets (0.57) | Return On Equity (1.04) |
The market value of Immix Biopharma is measured differently than its book value, which is the value of Immix that is recorded on the company's balance sheet. Investors also form their own opinion of Immix Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Immix Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immix Biopharma's market value can be influenced by many factors that don't directly affect Immix Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immix Biopharma Current Ratio vs. Short Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immix Biopharma's current stock value. Our valuation model uses many indicators to compare Immix Biopharma value to that of its competitors to determine the firm's financial worth. Immix Biopharma is rated second overall in short ratio category among its peers. It also is rated second overall in current ratio category among its peers fabricating about 6.64 of Current Ratio per Short Ratio. At this time, Immix Biopharma's Current Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immix Biopharma's earnings, one of the primary drivers of an investment's value.Immix Current Ratio vs. Short Ratio
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Immix Biopharma |
| = | 2.94 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Immix Biopharma |
| = | 19.53 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Immix Current Ratio Comparison
Immix Biopharma is currently under evaluation in current ratio category among its peers.
Immix Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immix Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immix Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Immix Biopharma's change in net profit over the period of time. It can combine multiple indicators of Immix Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 134.7 K | 120.4 K | |
| Net Interest Income | 343.4 K | 360.6 K | |
| Operating Income | -16.1 M | -15.3 M | |
| Net Loss | -14.2 M | -15 M | |
| Income Before Tax | -15.6 M | -16.3 M | |
| Total Other Income Expense Net | 572 K | 600.6 K | |
| Net Loss | -7.4 M | -7.8 M | |
| Net Loss | -15.6 M | -16.4 M | |
| Income Tax Expense | 26.4 K | 17.8 K | |
| Interest Income | 572 K | 314.6 K | |
| Change To Netincome | 717.7 K | 681.8 K | |
| Net Loss | (0.89) | (0.93) | |
| Income Quality | 0.73 | 0.46 | |
| Net Income Per E B T | 0.99 | 1.11 |
Immix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immix Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immix Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immix Biopharma's important profitability drivers and their relationship over time.
Use Immix Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immix Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will appreciate offsetting losses from the drop in the long position's value.Immix Biopharma Pair Trading
Immix Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Immix Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immix Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immix Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immix Biopharma to buy it.
The correlation of Immix Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immix Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immix Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immix Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immix Biopharma position
In addition to having Immix Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Oil And Gas Thematic Idea Now
Oil And Gas
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.